IPA
Income statement / Annual
Last year (2023), ImmunoPrecise Antibodies Ltd.'s total revenue was $24.52 M,
an increase of 18.65% from the previous year.
In 2023, ImmunoPrecise Antibodies Ltd.'s net income was -$27.18 M.
See ImmunoPrecise Antibodies Ltd.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
04/30/2024 |
04/30/2023 |
04/30/2022 |
04/30/2021 |
04/30/2020 |
04/30/2019 |
04/30/2018 |
04/30/2017 |
04/30/2016 |
12/31/2014 |
Operating Revenue |
$24.52 M
|
$20.67 M
|
$19.36 M
|
$17.91 M
|
$14.06 M
|
$10.93 M
|
$5.44 M
|
$2.63 M
|
$1.90 M
|
$1.76 M
|
Cost of Revenue |
$12.47 M |
$9.10 M |
$8.38 M |
$6.37 M |
$6.02 M |
$5.63 M |
$2.99 M |
$1.21 M |
$298,319.00 |
$265,333.00 |
Gross Profit |
$12.05 M |
$11.56 M |
$10.98 M |
$11.54 M |
$8.03 M |
$5.29 M |
$2.45 M |
$1.42 M |
$1.60 M |
$1.50 M |
Gross Profit Ratio |
0.49 |
0.56 |
0.57 |
0.64 |
0.57 |
0.48 |
0.45 |
0.54 |
0.84 |
0.85 |
Research and Development
Expenses |
$4.04 M
|
$12.28 M
|
$6.69 M
|
$1.97 M
|
$446,280.00
|
$485,845.00
|
$509,248.00
|
$660,408.00
|
$302,769.00
|
$621,639.00
|
General & Administrative
Expenses |
$15.59 M
|
$19.81 M
|
$16.97 M
|
$12.65 M
|
$7.95 M
|
$7.65 M
|
$6.31 M
|
$6.70 M
|
$997,291.00
|
$64,835.00
|
Selling & Marketing
Expenses |
$3.54 M
|
$3.61 M
|
$740,000.00
|
$691,000.00
|
$377,728.00
|
$819,250.00
|
$134,680.00
|
$119,192.00
|
$20,830.00
|
$6,693.00
|
Selling, General &
Administrative Expenses |
$19.14 M
|
$23.42 M
|
$17.71 M
|
$13.34 M
|
$8.33 M
|
$8.47 M
|
$6.45 M
|
$6.82 M
|
$1.02 M
|
$64,835.00
|
Other Expenses |
$0.00 |
$0.00 |
$2.75 M |
$132,000.00 |
$2.65 M |
$1.91 M |
$256,519.00 |
$376,776.00 |
$340,317.00 |
$1,040.00 |
Operating Expenses |
$25.82 M |
$39.78 M |
$27.15 M |
$15.71 M |
$12.08 M |
$11.52 M |
$7.21 M |
$7.84 M |
$1.66 M |
$65,875.00 |
Cost And Expenses |
$38.28 M |
$48.88 M |
$35.53 M |
$22.09 M |
$18.10 M |
$17.15 M |
$10.20 M |
$7.84 M |
$1.66 M |
$65,875.00 |
Interest Income |
$23,000.00 |
$270,000.00 |
$279,000.00 |
$282,000.00 |
$272,006.00 |
$30,085.00 |
$73,004.00 |
$0.00 |
$9,308.00 |
$0.00 |
Interest Expense |
$19,000.00 |
$30,000.00 |
$419,000.00 |
$863,000.00 |
$1.44 M |
$1.32 M |
$50,591.00 |
$16,216.00 |
$9,308.00 |
$338.00 |
Depreciation &
Amortization |
$5.74 M
|
$6.69 M
|
$3.77 M
|
$3.71 M
|
$3.41 M
|
$2.26 M
|
$458,079.00
|
$50,609.00
|
$41,881.00
|
$1,040.00
|
EBITDA |
-$8.00 M
|
-$21.26 M
|
-$12.12 M
|
-$181,000.00
|
-$366,261.00
|
-$3.93 M
|
-$4.43 M
|
-$5.16 M
|
$276,792.00
|
-$64,835.00
|
EBITDA Ratio |
-0.33 |
-1.03 |
-0.63 |
-0.01 |
-0.03 |
-0.36 |
-0.82 |
-1.96 |
0.15 |
-0.04 |
Operating Income Ratio
|
-0.56
|
-1.26
|
-0.81
|
-0.37
|
-0.29
|
-0.57
|
-0.91
|
-0.53
|
0.13
|
-0.02
|
Total Other
Income/Expenses Net |
-$14.95 M
|
$227,000.00
|
$462,000.00
|
-$1.24 M
|
-$82,316.00
|
-$99,216.00
|
-$323,182.00
|
-$239,827.00
|
$17,043.00
|
$3,900.00
|
Income Before Tax |
-$28.70 M |
-$27.75 M |
-$15.85 M |
-$6.00 M |
-$5.29 M |
-$7.61 M |
-$5.06 M |
-$5.47 M |
$242,646.00 |
-$62,313.00 |
Income Before Tax Ratio
|
-1.17
|
-1.34
|
-0.82
|
-0.33
|
-0.38
|
-0.7
|
-0.93
|
-2.08
|
0.13
|
-0.04
|
Income Tax Expense |
-$1.53 M |
-$1.19 M |
$861,000.00 |
$1.35 M |
-$345,728.00 |
$4,788.00 |
$109,715.00 |
-$82,378.00 |
$91,611.00 |
$338.00 |
Net Income |
-$27.18 M |
-$26.56 M |
-$16.71 M |
-$7.34 M |
-$4.95 M |
-$7.62 M |
-$5.17 M |
-$5.38 M |
$151,035.00 |
-$62,313.00 |
Net Income Ratio |
-1.11 |
-1.29 |
-0.86 |
-0.41 |
-0.35 |
-0.7 |
-0.95 |
-2.05 |
0.08 |
-0.04 |
EPS |
-1.06 |
-1.07 |
-0.85 |
-0.45 |
-0.36 |
-0.61 |
-0.57 |
-1.36 |
0.1 |
-0.11 |
EPS Diluted |
-1.06 |
-1.07 |
-0.85 |
-0.45 |
-0.36 |
-0.61 |
-0.57 |
-1.36 |
0.1 |
-0.11 |
Weighted Average Shares
Out |
$25.64 M
|
$24.90 M
|
$19.69 M
|
$16.47 M
|
$13.63 M
|
$12.54 M
|
$9.11 M
|
$3.96 M
|
$1.92 M
|
$550,129.00
|
Weighted Average Shares
Out Diluted |
$25.64 M
|
$24.90 M
|
$19.69 M
|
$16.47 M
|
$13.63 M
|
$12.54 M
|
$9.11 M
|
$3.96 M
|
$1.92 M
|
$550,129.00
|
Link |
|
|
|
|
|
|
|
|
|
|